Logotype for Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals (RYTM) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Rhythm Pharmaceuticals Inc

Q3 2026 earnings summary

3 Nov, 2026

Executive summary

  • Q3 global IMCIVREE net product revenue was $92.1M, up 29% QoQ and 80% YoY; reimbursed patients on therapy grew 20% globally.

  • U.S. acquired HO launch momentum continued, with more than 700 patient start forms from over 500 prescribers by Sept. 30; Japan commercialization began in October.

  • Bivamelagon is advancing toward Phase 3 trials for acquired HO and PWS; a revised LG Chem license and term-loan facility added financing capacity and future obligations.

Financial highlights

  • Q3 net product revenue was $92.1M versus $51.3M in Q3 2025 and $71.3M in Q2 2026.

  • Q3 U.S. product revenue was $67.5M; international revenue was $24.7M. U.S. revenue represented 73% of product revenue.

  • Q3 R&D expense was $52.5M and SG&A was $66.8M; operating expenses were $119.2M, including $25.0M in stock-based compensation.

  • GAAP diluted loss per share was $0.61 versus $0.82 in Q3 2025; cash, cash equivalents and short-term investments totaled $320.9M at Sept. 30.

Outlook and guidance

  • 2026 non-GAAP operating expense guidance is $360M–$380M: R&D $165M–$175M and SG&A $195M–$205M; guidance excludes stock-based compensation and fixed in-license and milestone consideration.

  • Cash at Sept. 30 is expected to fund planned operations for at least 24 months; that balance excludes the initial term-loan draw and the $70M LG Chem payment due.

  • A 52-week global placebo-controlled Phase 3 bivamelagon acquired-HO trial is planned, with BMI reduction as its primary endpoint; first sites are expected to screen by year-end 2026.

  • A six-month Phase 3 bivamelagon PWS study is planned for 2027, pending regulator alignment; acquired-HO launches in additional European countries are expected from 2027, beginning with Germany.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Rhythm Pharmaceuticals